Tempus AI

TEM · NASDAQ

$66.75+$2.41 (+3.75%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $64.34

TEM analyst rating

BuyConsensus of 18 analysts over the last 12 months. 61% rate it a buy.

Strong buy0
Buy11
Hold6
Underperform1
Sell0

12-month price target · 22 analysts

Average $71.92 (+7.7% upside)

Low: $35.35
Now: $66.75
High: $105.00

Upgrades and downgrades

The latest rating actions, newest first

TEM analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
JP Morgan	Oct 14, 2026	Maintains	Neutral	$45.00 → $70.00	71%
Canaccord Genuity	Oct 12, 2026	Maintains	Buy	$80.00 → $95.00	55%
Guggenheim	Oct 1, 2026	Maintains	Buy	$65.00 → $92.00	66%
Goldman Sachs	Sep 21, 2026	Initiates	Neutral	$75.00	73%
HC Wainwright & Co.	Sep 11, 2026	Maintains	Buy	$56.00 → $66.00	40%
UBS	Sep 9, 2026	Initiates	Neutral	$70.00	59%
Rothschild & Co	Sep 8, 2026	Initiates	Neutral	$67.00	67%
Roth Capital	Sep 8, 2026	Initiates	Neutral	$67.00	67%
Cantor Fitzgerald	Sep 2, 2026	Initiates	Overweight	$80.00	34%
Piper Sandler	Sep 1, 2026	Upgrade	Neutral → Overweight	$56.00 → $76.00	58%

The case for and against

Updated Oct 16, 2026

Bull case

Tempus AI is well positioned because its FDA-cleared ECG-PH product expands the cardiovascular portfolio to a third cleared offering, broadening the addressable market and reinforcing the scalability of its ECG-AI platform. Its positive outlook is further supported by the pending Personalis acquisition, which gains strategic validation from Merck and Moderna’s Phase 3 INTerpath-001 readout, while Personalis’ MRD coverage expansion and ASPs rising from about $139 in 4Q25 to $245 in 2Q26 strengthen the commercial case. Tempus also has a near-term earnings catalyst in xT CDx, with management expecting about $200 of ASP improvement per test and roughly $85 million of annual revenue beginning in 2027, alongside the possibility of about $400 million of incremental revenue in 2028 from unified ADLT pricing across xT and xF.

Bear case

Tempus AI is facing meaningful integration and execution risk from the Personalis acquisition, with NeXT Personal still in an early commercial ramp and only four MolDX coverage decisions in place, while no commercial payer contracts have been disclosed. Medicare coverage alone does not assure broader adoption because commercial payers represent about 50% of the eligible patient population, and their coverage decisions often lag MolDX by 12–24 months, extending the reimbursement overhang. Clinical and competitive uncertainty further दब दब दब?

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.